ELTS Score (CML)

The ELTS score uses a continuous mathematical model: 0.0025 × (age/10)³ + 0.0615 × (spleen) + 0.1052 × (blasts) + 0.4104 × (platelets/1000)⁻⁰.⁵.

The Sokal Score was developed in the 1980s (chemotherapy/interferon era). It tends to overestimate CML-related death in the era of modern TKIs like Imatinib and Nilotinib. The ELTS score was specifically designed to predict CML-specific mortality and identifies a larger proportion of low-risk patients with excellent outcomes.

Developed by the European Treatment and Outcome Study (EUTOS) group. It incorporates spleen size, age, blasts, and platelets into a non-linear model to reflect the modern natural history of TKI-treated CML.